Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189396 | 0.84 | ALDH1A1 (0.36) | ALDH1A1ALOX15NOTUMCES2CES1 | |
| SCHEMBL20509864 | 0.70 | ALDH1A1 (0.36) | ALDH1A1ALOX15NOTUM | |
| SCHEMBL19973994 | 0.69 | DGAT1 (0.36) | NOTUMCES2CES1 | |
| SCHEMBL28914080 | 0.66 | ALDH1A1 (0.31) | ALDH1A1CES2 | |
| SCHEMBL525011 | 0.63 | CES2 (0.67) | ALDH1A1ALOX15CES2CES1 | |
| SCHEMBL8308598 | 0.62 | ALDH1A1 (0.36) | ALDH1A1ALOX15CES2CES1 | |
| SCHEMBL110164 | 0.61 | ALDH1A1 (0.50) | ALDH1A1ALOX15CES2CES1 | |
| SCHEMBL14053008 | 0.61 | VHL (0.37) | NOTUM | |
| SCHEMBL1774412 | 0.60 | ALDH1A1 (0.48) | ALDH1A1ALOX15CES2CES1 | |
| SCHEMBL645757 | 0.60 | ALDH1A1 (0.54) | ALDH1A1ALOX15CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| WO-2018052967-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | ALDH1A1 3241/4885ALOX15 4718/4885NOTUM 2671/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | ALDH1A1 3241/4885ALOX15 4718/4885NOTUM 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.